Trials / Terminated
TerminatedNCT00595829
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Polycythemia Vera
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Exelixis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XL019 | XL019 capsules administered orally |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2009-02-01
- Completion
- 2009-02-01
- First posted
- 2008-01-16
- Last updated
- 2015-08-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00595829. Inclusion in this directory is not an endorsement.